R. Bryan Bell, MD, DDS, FACS, FRCS(Ed)

Cancer Institute Director. Head & Neck Surgeon. Clinical Researcher focused on #immunotherapy. Relentlessly working to #FinishCancer @Providence Tweets my own

[R. Bryan Bell, MD, DDS, FACS, FRCS(Ed) @rbryanbell]

I am deeply honored to succeed Dr. Urba & I am committed to building upon his legacy of transformational  immuno-oncology research & a world-class cancer center dedicated to translating the next generation of immunotherapies from lab bench to the bedside. @ChilesResearch

[Providence Oregon @ProvHealth]

Providence is excited to announce Bryan Bell, M.D., as executive medical director of Providence Cancer Institute and director of the Earle A. Chiles Research Institute @ChilesResearch. Walter Urba, M.D., Ph.D., wll retire at the end of the year. https://t.co/VNGawzp4uX

[R. Bryan Bell, MD, DDS, FACS, FRCS(Ed) @rbryanbell]

Farewell Chicago and #ASCO2026. Great week of science and better treatment for patients with cancer.
@ASCO
#FinishCancer
@providence
#HoodToCoast

[R. Bryan Bell, MD, DDS, FACS, FRCS(Ed) @rbryanbell]

Excited to see the updated first-in-human #ASCO2026 data for KLN-1010, an in vivo BCMA CAR-T therapy with promising early results in multiple myeloma.

Proud that @Providence Cancer Institute was the first site in the U.S. to open and enroll patients to this groundbreaking study.

[Eric Topol @EricTopol]

Another major advance vs cancer! @ASCO #ASCO26
Personalized neoantigen mRNA vaccine 5 year follow-up vs metastatic melanoma reduced recurrence and death by 49% (on top of Keytruda)
https://t.co/NadITTYIT2

[NEJM @NEJM]

Original Article: Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer (phase 3 RASolute 302 trial) https://t.co/y4G27hfORg

#ASCO26 | @ASCO

[R. Bryan Bell, MD, DDS, FACS, FRCS(Ed) @rbryanbell]

▪️ ARROW final analysis — pralsetinib in RET-altered thyroid cancer, 76% 2-yr DOR (Taylor)
▪️ PIKALO-1 tersolisib update — PI3Kα inhibitor in breast cancer (Page)
▪️ TAK-188 anti-CCR8 ADC — Treg-depleting therapy in solid tumors (Sanborn)

#FinishCancer @providence 🙏

[R. Bryan Bell, MD, DDS, FACS, FRCS(Ed) @rbryanbell]

Proud week for the Earle A. Chiles Research Institute at #ASCO2026 🧬

Highlights from our team at @providence:

▪️ M3T01 (FasL inhibitor) — conceived, developed & manufactured entirely at Providence, now through dose escalation & entering combo with anti-PD-1 (Taylor, Leidner)

[R. Bryan Bell, MD, DDS, FACS, FRCS(Ed) @rbryanbell]

▪️ NT-175 eTCR T-cell therapy — 47% ORR including 83% in pancreatic cancer (Leidner)
▪️ KEYNOTE-942 5-yr update — personalized neoantigen vaccine + pembro, durable benefit in resected melanoma (Taylor)

[R. Bryan Bell, MD, DDS, FACS, FRCS(Ed) @rbryanbell]

Great to be in Chicago for #ASCO2026 and the meeting is already delivering.

Today’s plenary presentation of the Phase III daraxonrasib trial showed a nearly doubling of survival in metastatic pancreatic cancer (13.2 vs 6.7 months). A landmark result for patients & the field.

[Yüksel Ürün @DrYukselUrun]

This is not simply a new pancreatic cancer drug.

It is a reminder that even “undruggable” biology can become treatable with persistence.

Daraxonrasib doubled median OS vs chemotherapy in RAS G12 metastatic pancreatic cancer: 13.2 vs 6.6 months.
A remarkable ASCO moment.
#ASCO26
@DrChoueiri @TiansterZhang @CathyEngMD @montypal @tompowles1 @brian_rini @cdanicas @GlopesMd @PGrivasMDPhD @nataliagandur @yekeduz_emre @neerajaiims @ASCO @ONCOassist @OpenMedicineHQ @MedwatchKate @scserendipity1 @CParkMD @urotoday @OncLive @crisbergerot @urologysummit @SuyogCancer @Larvol @IMG_Oncologists

[R. Bryan Bell, MD, DDS, FACS, FRCS(Ed) @rbryanbell]

At this year’s Creating Hope event, I had the privilege of sharing a glimpse of the future we are building at @Providence Cancer Institute.

Thank you to everyone who joined us in imagining—and helping create—a future where we #finishcancer .
https://t.co/y28tiOru5p

[R. Bryan Bell, MD, DDS, FACS, FRCS(Ed) @rbryanbell]

💥Now open @providence:
IMA203, a novel PRAME-targeted TCR-T cell therapy designed for patients w advanced solid tumors. Proud of our teams advancing next-gen cellular therapies & expanding access to innovative clinical trials for patients across the PNW. https://t.co/kd50pB6oLY

[R. Bryan Bell, MD, DDS, FACS, FRCS(Ed) @rbryanbell]

At @Providence Cancer Institute, Dr. Carlo Bifulco
is helping lead a precision oncology revolution, advancing how cancer is diagnosed and treated through comprehensive genomic profiling, digital pathology and responsible use of artificial intelligence. https://t.co/L9xM0NvpP5

[R. Bryan Bell, MD, DDS, FACS, FRCS(Ed) @rbryanbell]

Grateful to our donors, researchers, clinicians, patients & partners who are helping us create hope. From AI-driven pathology & precision oncology to early detection, cellular therapies, and first-in-human clinical trials, the future is what we make it. #FinishCancer
@providence

[R. Bryan Bell, MD, DDS, FACS, FRCS(Ed) @rbryanbell]

⁦@providence⁩ receives esteemed NIH grant for ‘paradigm shift’ in head and neck cancer treatments https://t.co/UjttdSMVpK

[R. Bryan Bell, MD, DDS, FACS, FRCS(Ed) @rbryanbell]

@HeartOTXHeartMD No advice- just happy birthday, old friend. (No pun intended 🙂)

[R. Bryan Bell, MD, DDS, FACS, FRCS(Ed) @rbryanbell]

Grateful for the warm welcome & outstanding exchange with @JosephMCurryMD & the team at the @JeffersonUniv.

Inspiring to connect around our shared mission to advance translational science & deliver cutting-edge cancer care. Looking forward to continued collaboration
@providence

[R. Bryan Bell, MD, DDS, FACS, FRCS(Ed) @rbryanbell]

The FDA has approved teclistamab (BCMA×CD3 bispecific) + daratumumab (CD38)—bringing powerful immune-based therapy and another inflection point in survival outcome.

A major step toward durable remissions—and potentially functional cure.

#FinishCancer
@providence

[R. Bryan Bell, MD, DDS, FACS, FRCS(Ed) @rbryanbell]

Real-world data shows WGS drives treatment decisions and improves outcomes beyond standard panels. It’s time for payers & legislators to evolve coverage & privacy policy to support comprehensive profiling & ensure equitable access to precision oncology. https://t.co/sPxUW1M900